Results 31 to 40 of about 4,502 (202)

Aprepitant Restores Corneal Sensitivity and Reduces Pain in DED [PDF]

Purpose: This study aims to assess the efficacy of two aprepitant formulations (X1 and X2), in a preclinical model of dry eye disease (DED) induced by benzalkonium chloride (BAK).
Ferrari G., Campestre F., Fonteyne P., Bonelli F., Demirsoy I. H., Vitar R. M. L.   +5 more
core   +2 more sources

Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush

Case Reports in Oncology, 2019
Common dermatological side-effects associated with erlotinib, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), include pruritus and skin rash, which are mediated by substance P, leading to the occasional discontinuation of cancer ...
Nobuhiko Seki, Ryosuke Ochiai, Terunobu Haruyama, Masashi Ishihara, Maika Natsume, Yoko Fukasawa, Takahiko Sakamoto, Shigeru Tanzawa, Ryo Usui, Takeshi Honda, Shuji Ota, Yasuko Ichikawa, Kiyotaka Watanabe   +12 more
doaj   +1 more source

Chemotherapy‐Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline‐Free Regimen With Docetaxel, Cyclophosphamide—Results From a Randomized Clinical Trial

International Journal of Cancer, EarlyView.
Chemotherapy‐induced nausea and vomiting (CINV) remains a significant clinical problem despite modern antiemetics. In particular, antiemetic strategies for emerging cancer therapies lack detailed evaluation. This randomized trial analyzed hourly CINV data for patients with early breast cancer who received either docetaxel plus cyclophosphamide (TC) or ...
Manuel Hörner, Henning Schäffler, Lothar Häberle, Chloë Goossens, Kerstin Pfister, Elena Leinert, Kristina Veselinovic, Sara Y. Brucker, Uwe Köhler, Georg Heinrich, Andreas Schneeweiss, Matthias W. Beckmann, Peter A. Fasching, Wolfgang Janni, Brigitte Rack, Sabine Heublein, Philipp Ziegler   +16 more
wiley   +1 more source

Effectiveness of Aprepitant in Patients with Refractory Pruritus Secondary to Sézary Syndrome [PDF]

, 2012
Background: In advanced stages, patients with Sézary Syndrome (SS) commonly report an ill-defined, severe and diffuse pruritus. Recently, it has been reported that Aprepitant, an oral neurokinin-1-receptor (NK1) antagonist, may have an important role in ...
Fernandes, I., Torres, T., Lima, M., Selores, M., Alves, R.   +4 more
core  

Aprepitant in Adolescent Patients for Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Tolerability

, 2009
Background. the neurokinin-1 receptor antagonist aprepitant, plus a 5HT3 antagonist and corticosteroid is well-tolerated and effective in preventing chemotherapy-induced nausea and vomiting in adults but has not been formally assessed in adolescents ...
Valentine, Jack, Evans, Judith K., Chua, Vickey, Adolescent Aprepitant Canc Study G, Gore, Lia, Carides, Alexandra D., Oxenius, Bettina, Hemenway, Molly, Taylor, Arlene, Schissel, Debra, Petrilli, Antonio [UNIFESP], DeVandry, Suzanne, Chawla, Sant   +12 more
core   +1 more source

Stability of Aprepitant Injectable Emulsion in Alternate Infusion Bags, in Refrigerated Storage, and Admixed with Dexamethasone and Palonosetron

Drug Design, Development and Therapy, 2021
Thomas Ottoboni, 1 Laura Lerner, 1 Arlene Santhouse 2 1Pharmaceutical and Translational Science, Heron Therapeutics, Inc, San Diego, CA, USA; 2Medical Affairs, Heron Therapeutics, Inc, San Diego, CA, USACorrespondence: Thomas OttoboniPharmaceutical and
Ottoboni T, Lerner L, Santhouse A
doaj  

Evaluating Aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: A triple-blinded randomized clinical trial

Hematology, Transfusion and Cell Therapy, 2023
Introduction: This study was performed to evaluate the degree of 3-day chemotherapy-induced nausea and vomiting (CINV) in children with cancer who received highly emetogenic chemotherapy (HEC) to ascertain the efficacy of aprepitant single-dose on dayL 1
Aziz Eghbali, Fatemeh Khazaei Kohpar, Kazem Ghaffari, Roghayeh Rahimi Afzal, Aygin Eghbali, Ali Ghasemi   +5 more
doaj   +1 more source

Review of nutrition management of pediatric intestinal pseudo‐obstruction

Nutrition in Clinical Practice, EarlyView.
Abstract Chronic intestinal pseudo‐obstruction (CIPO) is a rare, heterogeneous, and debilitating disorder characterized by profound intestinal dysmotility and severe nutrition challenges. Its presentation resembles that of mechanical bowel obstruction, but CIPO occurs in the absence of luminal obstruction.
Senthilkumar Sankararaman, Raisa Rani James, Bushra El‐Amaireh, Andrea Adler, Kadakkal Radhakrishnan, Sujithra Velayuthan   +5 more
wiley   +1 more source

Neurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysis

Therapeutic Advances in Medical Oncology, 2016
A network meta-analysis of the comparative effectiveness of neurokinin 1 (NK-1) inhibitors in the prophylaxis of highly emetogenic chemotherapy induced nausea and vomiting has been conducted.
Omar Abdel-Rahman
doaj   +1 more source

Broadening the View: Substance P and Its Metabolism in Pruritus‐Related Diseases

The Journal of Dermatology, EarlyView.
ABSTRACT Chronic pruritus is a debilitating symptom accompanying numerous inflammatory skin diseases and remains a major therapeutic challenge. Neurogenic inflammation plays a central role in its pathogenesis, with the tachykinin substance P acting as a key mediator at the interface of the nervous system, immune cells, and cutaneous tissues.
Thomas Walter, Bjoern B. Burckhardt
wiley   +1 more source